Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine

Current Eye Research

Volumn 21, Issue 4, 2000, Pages 814-819

  Kowluru, R A ^a   Engerman, R L ^a   Kern, T S ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Aminoguanidine; Nitric oxides; Oxidative stress; Retinopathy

Indexed keywords

AMINOGUANIDINE; GALACTOSE; GLUTATHIONE; HEXOSE; NITRIC OXIDE; PROTEIN KINASE C; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME ACTIVITY; GALACTOSEMIA; HYPERGLYCEMIA; METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DIET; GALACTOSEMIAS; GLUTATHIONE; GUANIDINES; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RETINA; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0034493893     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.21.4.814.5545     Document Type: Article

References (38)

1. Experimental galactosemia produces diabetic-like retinopathy
2. Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats
3. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors
4. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats
5. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor
6. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases
7. Relationship of lipid peroxides to diabetic complications
8. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system
9. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
10. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease
11. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine
12. Aminoguanidine prevents diabetes-induced arterial wall protein cross linking
13. Advanced glycosylation endproducts in experimental murine diabetic nephropathy: Effect of islet isografting and of aminoguanidine
14. Aminoguanidine inhibits oxidative modification of low density lipoprotein the subsequent increase in uptake by macrophage scavenger receptors
15. Aminoguanidine: A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro
16. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation endproduct formation
17. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction
18. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals
19. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
20. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: Comparison of diabetes and galactosemia
21. Lipofuscin products, lipid peroxides and aluminum accumulation in red blood cells of hemodialyzed patients
22. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VI. Comparison of retinal and cerebral cortex metabolism, and effects of antioxidant therapy
23. Abnormalities of retinal metabolism in diabetes or galactosemia. ATPases and glutathione
24. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase
25. Mechanism of inducible nitric oxide synthase inactivation by aminoguanidine and L-N6-(1-iminoethyl) lysine
26. Characterization of the mechanism for the chronic activation of DAG-PKC pathway in diabetes and hypergalactosemia
27. Hydrogen peroxide production during experimental protein glycation
28. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis
29. The glutathione levels are reduced in Goto-Kakizaki rat retina, but are not influenced by aminoguanidine treatment
30. Nitric oxide in streptozotocin diabetic rats
31. The linked roles of nitric oxide, aldose reductase and, (Na,K)-ATPase in the slowing of nerve conduction velocity in streptozotocin diabetic rats
32. Nitric oxide and ocular blood flow in patients with IDDM
33. Role of nitric oxide in retinal cell death
34. Nitric oxide synthase activity and L-arginine metabolism in the retinas from streptozotocin-induced diabetic rats
35. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products
36. Modulation of activator protein-1 (AP-1) transcription factor and protein kinase C by hydrogen peroxide and D-α-tocopherol in vascular smooth muscles
37. Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells
38. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats